{"text_format":"1","workbook":"xlsx","n_sheets":10,"sheets":["Intro","Baseline 1","Baseline 2","Figures","Print (ITT)","Print (PP)","Check","Print_format (PP)","Print_format (ITT)","Function Tab"],"not_rendered":{"charts":0,"images":5,"macros":1,"external_links":0,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Intro","index":0,"n_rows":9,"n_cols":22,"rows_kept":9,"cut":false,"hidden":false,"merged":[]}
[]
[]
[]
[]
[]
[]
[]
[]
[null,"Instructions for the assessment form",null,null,null,null,"Instructions for the summary",null,null,null,null,"Instructions for the figure",null,null,null,null,"Instructions for generating a print view",null,null,null,null,"Instructions for the discrepancy check"]

{"sheet":"Baseline 1","index":1,"n_rows":15,"n_cols":17,"rows_kept":15,"cut":false,"hidden":false,"merged":[]}
["Study ID","Country","Site","NOS/Jaded score","Age (I vs C)","N (used GC vs didn't use GC)","Gender                                                 Male/Total (I vs C)","Coluna10","Coluna1","Coluna2","Coluna3","Coluna4","Coluna5","Coluna6","Coluna7","Coluna8","Coluna9"]
["Guan","China","Multi-center",5,"Severe: 52.0 (40.0–65.0) Nonsevere: 45.0 (34.0–57.0)","204; 895","Severe: 100/173 Nonsevere: 537/923"]
["Yang","China","Single center",6,"Survivors: 51·9 (12·9) Nonsurvivors: 64·6 (11·2)","30; 22","Survivors: 14/20   Nonsurvivors: 21/32"]
["Zhou","China","Two centers",6,"Survivors: 52·0 (45·0–58·0) Nonsurvivors: 69·0 (63·0–76·0)","57; 134","Survivors: 81/137 Nonsurvivors: 38/54"]
["Cao","China","Single center",6,"Survivors: 53 (47-66) Nonsurvivors: 72 (63-81)","51; 51","Survivors: 40/85 Nonsurvivors: 13/17"]
["Salacup","USA","Single center",6,"Survivors: 64.08±15.07 Nonsurvivors: 73.15±11.01","55; 187","Survivors: 96/190 Nonsurvivors: 27/52"]
["Li","China","Single center",6,"Survivors: 62 (53-70) Nonsurvivors: 71 (69-77)","70; 4","Survivors: 33/60 Nonsurvivors: 11/14"]
["Zha","China","Two centers",8,"Corticosteroid: 53 (36–57) Noncorticosteroid: 37 (27–52)","11; 20","Corticosteroid: 8/11 Noncorticosteroid: 12/20"]
["Wang","China","Single center",8,"Corticosteroid: 54(48,63) Noncorticosteroid: 53(48,63)","26; 20","Corticosteroid: 16/26 Noncorticosteroid: 10/20"]
["Gong","China","Single center",4,"Corticosteroid: 38.22 ± 8.95 Noncorticosteroid: 33.75 ± 7.80","18; 16","Corticosteroid: 11/18 Noncorticosteroid: 11/16"]
["Cruz","Spain","Single center",7,"Corticosteroid: 65.4 (12.9) Noncorticosteroid: 68.1 (15.7)","396; 67","Corticosteroid: 276/396 Noncorticosteroid: 41/67"]
["Fang","China","Single center",7,"Corticosteroid: General group - 40.2±12.6. Severe Group - 60.6±13.6                                        Noncorticosteroid: General group - 39.9±15.5. Severe group - 54.3±15.4 ","25; 53","Corticosteroid: General group - 5/9. Severe Group - 12/16                                     Noncorticosteroid: General group - 22/46. Severe group - 5/7 "]
["Wu","China","Single center",6,"Without ARDS: 48.0 (40.0 to 54.0)     With ARDS: 58.5 (50.0 to 69.0)","62; 139","Without ARDS: 68/117                     With ARDS: 60/84"]
["Shang","China","Multi-center",6,"Survivors: Common - 46·0(33·0~56·0). Severe - 50·0(38·0~60·0)                       Death: 67·0(61·0~77·0)","196; 220","Survivors: Common - 89/226. Severe - 77/139                                   Death: 31/51"]
["Xu","China","Two centers",6,"<15 days to viral clearance: 48 (34, 61)    >15 days to viral clearance: 54,5 (45, 63)","64/49","<15 days to viral clearance: 15/37   >15 days to viral clearance: 51/76"]

{"sheet":"Baseline 2","index":2,"n_rows":15,"n_cols":17,"rows_kept":15,"cut":false,"hidden":false,"merged":[]}
["Study ID","Severity of disease","Type, dose and duration","Outcome","Result","Coluna1","Coluna2","Coluna3","Coluna4","Coluna5","Coluna6","Coluna7","Coluna8","Coluna9","Coluna10","Coluna11","Coluna12"]
["Guan","Severe/ Nonsevere","Systemic glucocorticoids","Admission to an  (ICU), the use of mechanical ventilation, or death","Higher percentage among those without outcome"]
["Yang","Critically ill","Glucocorticoids","28-day mortality after ICU admission","Higher percentage among those without outcome"]
["Zhou","All","Corticosteroids","Mortality","Higher percentage among those  with outcome with statistical difference"]
["Cao","All","Methylprednisolone Sodium Succ","Mortality","Higher percentage among those with outcome but no statistical difference"]
["Salacup","All","Steroids","Mortality","Higher percentage among those  with outcome with statistical difference"]
["Li","Severe and critical","Corticosteroids","Mortality","Higher percentage among those without outcome but no statistical difference"]
["Zha","Mild","40 mg Methylprednisolone once or twice per day within 24 hours of admission for a median 5 days","Time to virus clearance","No statistically significant differences in virologic or clinical outcomes between patients who received and those who did not receive corticosteroid"]
["Wang","Severe","Methylprednisolone treatment with the dosage of 12mg/kg/d for 5-7 days","Clinical, laboratory and radiological improvement","Better statistically significant improvement among those who received methylprednisolone in duration of fever, Sp02 and absorption degree of the focus in chest CT "]
["Gong","All","Methylprednisolone as  1-2mg/kg/d in  the initial dose and gradually halved every 3 days, total treating course range from 5 to 10 days","Viral genomic nucleic acid negative conversion and CT imaging lesion absorption ","No statistical difference in the  CT imaging lesion absorption  in both 2 groups but shorter time needed to viral genomic nucleic acid negative conversion in the methylprednisolone group "]
["Cruz","COVID-19 patients complicated with ARDS and/or an hyperinflammatory syndrome","1 mg/kg/day Methylprednisolone or equivalent, and steroid pulse","In-hospital mortality","In-hospital mortality was lower in patients treated with steroids than in controls"]
["Fang","General and severe","Oral methylprednisolone, 237.5 mg/day for a median duration of 7 days in the general group. Intravenous methylprednisolone, 250.0 mg/day for a median duration of 4.5 days in the severe group","Time to virus clearance","No significant difference identified in both patients in the general group  and patients in the severe group"]
["Wu","All","Methylprednisolone ","Development of ARDS and death among those with ARDS","Patients who developed ARDS were more likely to be treated with methylprednisolone and the administration of methylprednisolone appears to have reduced the risk of death in patients with ARDS"]
["Shang","All","methylprednisolone, prednisone acetate, and dexamethasone","Hospitalization time and clinical and laboratory changing","Survivors who received corticosteroid therapy had a longer duration of hospitalization and there was a significant recovery of lymphocyte counts after corticosteroids therapy for the survivors but not the deaths."]
["Xu","All","Corticosteroids","Time to virus clearance","Higher percentage among the > 15 days to virus clearence group with statistical difference"]

{"sheet":"Figures","index":3,"n_rows":1,"n_cols":30,"rows_kept":1,"cut":false,"hidden":false,"merged":[]}
["Studies with intention-to-treat","Unique ID","Study ID","Experimental","Comparator","Outcome","Weight","Randomization process","Deviations from intended interventions","Missing outcome data","Measurement of the outcome","Selection of the reported result","Overall",null,null,null,null,"Studies with pre-protocol","Unique ID","Study ID","Experimental","Comparator","Outcome","Weight","Randomization process","Deviations from intended interventions","Missing outcome data","Measurement of the outcome","Selection of the reported result","Overall"]

{"sheet":"Print (ITT)","index":4,"n_rows":0,"n_cols":0,"rows_kept":0,"cut":false,"hidden":false,"merged":[]}

{"sheet":"Print (PP)","index":5,"n_rows":0,"n_cols":0,"rows_kept":0,"cut":false,"hidden":false,"merged":[]}

{"sheet":"Check","index":6,"n_rows":0,"n_cols":0,"rows_kept":0,"cut":false,"hidden":false,"merged":[]}

{"sheet":"Print_format (PP)","index":7,"n_rows":32,"n_cols":6,"rows_kept":32,"cut":false,"hidden":true,"merged":[[18,5,19,5],[24,5,25,5],[4,1,4,3],[5,0,8,0],[5,1,5,3],[5,5,6,5],[6,1,6,3],[7,1,7,3],[8,1,8,3],[9,5,10,5],[10,1,10,3],[11,1,11,3],[12,1,12,3],[13,1,13,3],[9,0,15,0],[9,1,9,3],[14,1,14,3],[15,1,15,3],[16,0,20,0],[16,1,16,3],[17,1,17,3],[18,1,18,3],[20,1,20,3],[19,1,19,3],[31,1,31,3],[21,0,26,0],[21,1,21,3],[22,1,22,3],[26,1,26,3],[23,1,23,3],[25,1,25,3],[24,1,24,3],[29,1,29,3],[27,0,30,0],[27,1,27,3],[28,1,28,3],[30,1,30,3]]}
["Unique ID",null,"Study ID",null,"Assessor"]
["Ref or Label",null,"Aim","adhering to intervention (the 'per-protocol' effect)","The effect of adhering to intervention…"]
["Experimental",null,"Comparator",null,"Source"]
["Outcome",null,"Results",null,"Weight"]
["Domain","Signalling question",null,null,"Response","Comments"]
["Bias arising from the randomization process","1.1 Was the allocation sequence random?"]
[null,"1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?"]
[null,"1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?"]
[null,"Risk of bias judgement"]
["Bias due to deviations from intended interventions","2.1 Were participants aware of their assigned intervention during the trial?"]
[null,"2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?"]
[null,"2.3. [If applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non-protocol interventions balanced across intervention groups?"]
[null,"2.4. [If applicable:] Were there failures in implementing the intervention that could have affected the outcome?"]
[null,"2.5. [If applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes?"]
[null,"2.6. If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the intervention?"]
[null,"Risk of bias judgement"]
["Bias due to missing outcome data","3.1 Were data for this outcome available for all, or nearly all, participants randomized?"]
[null,"3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?"]
[null,"3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?"]
[null,"3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?"]
[null,"Risk of bias judgement"]
["Bias in measurement of the outcome","4.1 Was the method of measuring the outcome inappropriate?"]
[null,"4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?"]
[null,"4.3 Were outcome assessors aware of the intervention received by study participants?"]
[null,"4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?"]
[null,"4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?"]
[null,"Risk of bias judgement"]
["Bias in selection of the reported result","5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?"]
[null,"5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?"]
[null,"5.3 ... multiple eligible analyses of the data?"]
[null,"Risk of bias judgement"]
["Overall bias","Risk of bias judgement"]

{"sheet":"Print_format (ITT)","index":8,"n_rows":33,"n_cols":6,"rows_kept":33,"cut":false,"hidden":true,"merged":[[19,5,20,5],[25,5,26,5],[5,0,8,0],[5,1,5,3],[5,5,6,5],[6,1,6,3],[7,1,7,3],[8,1,8,3],[9,5,10,5],[10,1,10,3],[11,1,11,3],[12,1,12,3],[20,1,20,3],[17,0,21,0],[17,1,17,3],[18,1,18,3],[4,1,4,3],[9,0,16,0],[9,1,9,3],[13,1,13,3],[14,1,14,3],[16,1,16,3],[15,1,15,3],[19,1,19,3],[21,1,21,3],[32,1,32,3],[22,0,27,0],[22,1,22,3],[23,1,23,3],[27,1,27,3],[24,1,24,3],[25,1,25,3],[26,1,26,3],[30,1,30,3],[28,0,31,0],[28,1,28,3],[29,1,29,3],[31,1,31,3]]}
["Unique ID",null,"Study ID",null,"Assessor"]
["Ref or Label",null,"Aim","assignment to intervention (the 'intention-to-treat' effect)\n\n"]
["Experimental",null,"Comparator",null,"Source"]
["Outcome",null,"Results",null,"Weight"]
["Domain","Signalling question",null,null,"Response","Comments"]
["Bias arising from the randomization process","1.1 Was the allocation sequence random?"]
[null,"1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?"]
[null,"1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?"]
[null,"Risk of bias judgement"]
["Bias due to deviations from intended interventions","2.1.Were participants aware of their assigned intervention during the trial?"]
[null,"2.2.Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?"]
[null,"2.3. If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?"]
[null,"2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?"]
[null,"2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?"]
[null,"2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?"]
[null,"2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?"]
[null,"Risk of bias judgement"]
["Bias due to missing outcome data","3.1 Were data for this outcome available for all, or nearly all, participants randomized?"]
[null,"3.2 If N/PN/NI to 3.1: Is there evidence that result was not biased by missing outcome data?"]
[null,"3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?"]
[null,"3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?"]
[null,"Risk of bias judgement"]
["Bias in measurement of the outcome","4.1 Was the method of measuring the outcome inappropriate?"]
[null,"4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?"]
[null,"4.3 Were outcome assessors aware of the intervention received by study participants?"]
[null,"4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?"]
[null,"4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?"]
[null,"Risk of bias judgement"]
["Bias in selection of the reported result","5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?"]
[null,"5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?"]
[null,"5.3 ... multiple eligible analyses of the data?"]
[null,"Risk of bias judgement"]
["Overall bias","Risk of bias judgement"]

{"sheet":"Function Tab","index":9,"n_rows":12,"n_cols":19,"rows_kept":12,"cut":false,"hidden":true,"merged":[]}
[null,"Journal article(s) with results of the trial","NA","Yes",null,"1.1 Was the allocation sequence random?",null,"2.1 Were participants aware of their assigned intervention during the trial?","2.1 Were participants aware of their assigned intervention during the trial?",null,"3.1 Were data for this outcome available for all, or nearly all, participants randomized?","Individually Randomized, Parallel Group Trials","4.1 Was the method of measuring the outcome inappropriate?","assignment to intervention (the 'intention-to-treat' effect)","5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?",null,null,null,"occurance of non-protocol interventions"]
["NA","Trial protocol","Favours experimental ","No (Please include reasons in the note)","Y","1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?","Low","2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?","2.2 Were carers and people delivering the interventions aware of participants' assigned intervention during the trial?",null,"3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?",null,"4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?","adhering to intervention (the 'per-protocol' effect)","5.2 ... multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?",null,null,null,"failures in implementing the intervention that could have affected the outcome"]
["Y","Statistical analysis plan (SAP)","Favours comparator ",null,"PY","1.3 Did baseline differences between intervention groups suggest a problem with the randomization process?","High","2.3 [if applicable:] If Y/PY/NI to 2.1 or 2.2: Were important non- protocol interventions balanced across intervention groups?","2.3 If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that arose because of the experimental context?",null,"3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value?",null,"4.3 If N/PN/NI to 4.1 and 4.2: Were outcome assessors aware of the intervention received by study participants?",null,"5.3 ... multiple eligible analyses of the data?",null,null,null,"non-adherence to their assigned intervention by trial participants"]
["PY","Non-commercial trial registry record (e.g. ClinicalTrials.gov record)","Towards null ",null,"PN",null,"Some concerns","2.4 [if applicable:] Were there failures in implementing the intervention that could have affected the outcome?","2.4 If Y/PY to 2.3: Were these deviations likely to have affected the outcome?",null,"3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?",null,"4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?"]
["PN","Company-owned trial registry record (e.g. GSK Clinical Study Register record)","Away from null ",null,"N",null,null,"2.5 [if applicable:] Was there non-adherence to the assigned intervention regimen that could have affected participants’ outcomes?","2.5. If Y/PY/NI to 2.4: Were these deviations from intended intervention balanced between groups?",null,null,null,"4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?"]
["N","“Grey literature” (e.g. unpublished thesis)","Unpredictable",null,"NI",null,null,"2.6 If N/PN/NI to 2.3, or Y/PY/NI to 2.4 or 2.5: Was an appropriate analysis used to estimate the effect of adhering to the intervention?","2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?"]
["NI","Conference abstract(s) about the trial",null,null,null,null,null,null,"2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?"]
[null,"Regulatory document (e.g. Clinical Study Report, Drug Approval Package)"]
[null,"Research ethics application"]
[null,"Grant database summary (e.g. NIH RePORTER, UKRI Gateway to Research)"]
[null,"Personal communication with trialist"]
[null,"Personal communication with the sponsor"]